Commercial Insight: Osteoporosis - Risk Management and Reformulation Offer Best Defense against Generic Onslaught.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c62454) has announced the addition of Commercial Insight: Osteoporosis osteoporosis (ŏs'tēō'pərō`sĭs), disorder in which the normal replenishment of old bone tissue is severely disrupted, resulting in weakened bones and increased risk of fracture; osteopenia - Risk Management and Reformulation Offer Best Defense against Generic Onslaught to their offering. The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate alendronate /alen·dro·nate/ (ah-len´dro-nat) a bisphosphonate calcium-regulating agent used in the form of the sodium salt to inhibit the resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related ) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years. Scope of this title: This report focuses on the leading therapies used in osteoporosis, with sales and volume country- and indication-specific forecasts to 2016. Assessment of current and future opportunities and threats in the osteoporosis market across the seven major pharmaceutical markets. Future market events that are expected to affect drug revenues are discussed and quantified for each of the seven major markets. Lifecycle management case studies show how previously successful strategies should be applied in today's market. Highlights of this title: Reformulations of marketed products have helped rejuvenate re·ju·ve·nate tr.v. re·ju·ve·nat·ed, re·ju·ve·nat·ing, re·ju·ve·nates 1. To restore to youthful vigor or appearance; make young again. 2. the calcitonin calcitonin /cal·ci·to·nin/ (-to´nin) a polypeptide hormone secreted by C cells of the thyroid gland, and sometimes of the thymus and parathyroids, which lowers calcium and phosphate concentration in plasma and inhibits bone resorption. and bisphosphonate markets amid genericization. Arguably ar·gu·a·ble adj. 1. Open to argument: an arguable question, still unresolved. 2. That can be argued plausibly; defensible in argument: three arguable points of law. the most exciting is the Roches Boniva (ibandronate) reformulation which will generate substantial revenue as both an oral monthly and injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. quarterly product. Following a number of recent reports that have concluded that vitamin D vitamin D Any of a group of fat-soluble alcohols important in calcium metabolism in animals to form strong bones and teeth and prevent rickets and osteoporosis. It is formed by ultraviolet radiation (sunlight) of sterols (see steroid) present in the skin. and calcium supplementation calcium supplementation Metabolism The addition of Ca2+ to the diet, usually in the form of calcium carbonate decreases the risk of cancer there is further support for the strategy to include a popular supplementary medication as either a combination pill or separately within the prescription brand packaging. Eli Lilly Eli Lilly can refer to:
Reasons to order your copy: Assess the impact of events such as patent expiries and new product launches on the osteoporosis sales of key marketed products Quantify the future size of the osteoporosis market, in terms of volume and value, in each of the seven major markets Identify key lifecycle management strategies that can ensure long term growth in the competitive osteoporosis market Content Outline: Chapter 1. Executive summary Chapter 2. Market definition and overview Chapter 3. Country market assessments Chapter 4. Forecast analysis Chapter 5. Commercial impact and lifecycle management: case studies BIBLIOGRAPHY APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS APPENDIX B - MARKET FORECAST DATA APPENDIX C For more information visit http://www.researchandmarkets.com/reports/c62454 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion